Skip to main content

Arch Biopartners Inc(ARCH-X)
TSX Venture

Today's Change
Delayed Last Update

Arch Biopartners Inc

545 King Street West
Toronto ON M5V 1M1 CAN
P: 647-428-7031
F: 647-351-3565

Sectors & Indices



Arch Biopartners Inc is a clinical stage company developing technologies with the potential to make medical or commercial impacts. The company is developing a drug platform Metablok to produce drug candidates to inhibit organ inflammation caused via the DPEP-1 pathway. It's under development portfolio is AB569, a potential new treatment for antibiotic resistant bacterial infections in the lungs or wounds; and, Borg peptide coatings that increase corrosion resistance and decrease bacterial biofilm on various medical grade metals and plastics.

Key Executives

Richard MuruveCEO/Co-Founder/Director/President
Andrew BishopCFO/Director
Daniel MuruveChief Scientific Officer/Co-Founder